Archer Investment Corp Makes New $321,000 Investment in Oruka Therapeutics, Inc. $ORKA

Archer Investment Corp purchased a new stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,546 shares of the company’s stock, valued at approximately $321,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Viking Global Investors LP purchased a new stake in shares of Oruka Therapeutics in the 3rd quarter worth approximately $51,280,000. Paradigm Biocapital Advisors LP purchased a new position in Oruka Therapeutics during the fourth quarter valued at approximately $51,840,000. Remedium Capital Partners LLC bought a new position in Oruka Therapeutics in the fourth quarter worth approximately $47,054,000. Deep Track Capital LP raised its stake in Oruka Therapeutics by 38.4% in the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after buying an additional 735,983 shares in the last quarter. Finally, State Street Corp lifted its holdings in Oruka Therapeutics by 112.2% during the fourth quarter. State Street Corp now owns 1,383,847 shares of the company’s stock worth $41,944,000 after buying an additional 731,819 shares during the period. 56.44% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ORKA has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 23rd. Guggenheim set a $200.00 price objective on Oruka Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 27th. UBS Group raised their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Piper Sandler reiterated an “overweight” rating and issued a $180.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Finally, Barclays boosted their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $134.30.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30. Following the completion of the sale, the senior vice president owned 16,406 shares of the company’s stock, valued at approximately $969,102.42. The trade was a 38.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the sale, the chief executive officer owned 925,580 shares in the company, valued at approximately $64,503,670.20. The trade was a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 188,406 shares of company stock worth $12,019,683. Insiders own 23.49% of the company’s stock.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $87.47 on Wednesday. Oruka Therapeutics, Inc. has a fifty-two week low of $12.84 and a fifty-two week high of $97.78. The firm has a market capitalization of $5.28 billion, a price-to-earnings ratio of -45.09 and a beta of -0.35. The stock’s 50-day simple moving average is $71.24 and its 200-day simple moving average is $52.26.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. As a group, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.